This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
Continuous Drug Delivery: Advancements in nAMD and DME (CME Podcast)
MedEdicus Podcasts
51 minutes
8 months ago
Continuous Drug Delivery: Advancements in nAMD and DME (CME Podcast)
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
